Preliminary investigation in 70 cases of PCS that underwent molecular analysis demonstrated potentially actionable aberrations including amplification ofMDM2 and PDGFRA. 22 This is supported by preclinical work in intimal sarcoma (a subtype of sarcoma akin to PCS arising in large arteries) where PDGFRA amplifications are common, together with activation of EGFR and MDM2. These mutations support the investigation of receptor tyrosine kinases blocking downstream pathways.23, 24. This evidence concerns the gene MDM2 and sarcoma.